COLUMBUS, Ohio--Signet Accel has been contracted to deliver and implement a cancer research information exchange (RIE) platform at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), promising true interoperability in big data and increased speed to discovery.
@OSUCCC_James looks to @SignetAccelLLC's Avec™ to power #precisionmedicine and link multiple centers in #cancer RIE.Tweet this
“With Avec, we bring a proven platform for data integration and sharing in what are undeniably complex healthcare and research environments,” said John Raden, Signet Accel chief executive officer. “True interoperability powers precision medicine by offering full access to all possible data, and in turn presents researchers with the most complete answer. By eliminating the need for duplication, we’re reducing the time it takes investigators to see real results.”
Robust repositories of connected data are a key resource in realizing the promise of precision medicine, a research effort aimed at improving health and treating disease by accounting for patients’ individual differences. Signet Accel’s federated data integration platform provides the ability to connect and harmonize such disparate databases, allowing researchers to identify patterns and trends across a large patient population and offering comprehensive insight into cancer research and treatment.
“Precision medicine means personalized treatment, where the right patient receives the right treatment at the right time. It’s our goal to customize treatments to each individual patient, and deliver those treatments in a timely manner. The use of big data is central to that goal,” said Michael Caligiuri, MD, director of the OSUCCC and chief executive officer of The James. “With a pristine repository of consented data, including genomic and biospecimen data, we can quickly search for certain patients with certain characteristics and then be able to target their therapies, thereby saving more lives.”
The multi-phase initiative will allow for a federated oncology-focused RIE, resulting in enabled data sharing, identification and matching of potential participants for cancer research studies. Deployment at The Ohio State University and the H. Lee Moffitt Cancer Center & Research Institute is planned for August 2016.
“We enable our clients to harness the power of dynamic and multi-dimensional data in healthcare, for more complete answers than ever before,” said Raden. “There’s a perception in the healthcare industry that true interoperability just isn’t possible. We’re here to dispel that doubt. It’s happening now, and it can be done in a way that not only benefits investigators, clinicians and patients, but also the bottom line—without sacrificing data ownership or patient privacy. I can think of nothing more rewarding than empowering our clients to bring more data to the fight against cancer. ”
About Signet Accel
Signet Accel’s Avec™ platform is true interoperability realized in healthcare. As the sole alternative to traditional, centralized data management solutions, Avec™ delivers the industry's only purpose-built commercial federated data integration platform, developed and refined over 12 years at The Ohio State University. Signet Accel’s software products and services power the work of consortia, institutions, and health professionals around the world with unmatched security, sharing capability and speed of discovery —advancing academic research, achieving meaningful use objectives, and enabling the continuum of care. Learn how to make your data meaningful and achieve true interoperability with SignetAccel.com
About The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 46 National Cancer Institute-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs. As the cancer program’s 306-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. At 21 floors with more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. For more information, visit cancer.osu.edu.